Senescence in tumours: evidence from mice and humans (original) (raw)

• Hayflick, L. & Moorhead, P. S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 25, 585–621 (1961).
  Article CAS Google Scholar
• Collado, M., Blasco, M. A. & Serrano, M. Cellular senescence in cancer and aging. Cell 130, 223–233 (2007).
  Article CAS Google Scholar
• Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D. & Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593–602 (1997). The original description of oncogene-induced senescence in primary human and mouse cells cultured in vitro after the overexpression of oncogenic HRAS. It prompted the idea of cellular senescence as a tumour suppressor mechanism.
  Article CAS Google Scholar
• Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307–315 (2004).
  Article CAS Google Scholar
• Braig, M. et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660–665 (2005).
  Article CAS Google Scholar
• Chen, Z. et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436, 725–730 (2005).
  Article CAS Google Scholar
• Collado, M. et al. Tumour biology: senescence in premalignant tumours. Nature 436, 642 (2005).
  Article CAS Google Scholar
• Lazzerini Denchi, E., Attwooll, C., Pasini, D. & Helin, K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol. Cell Biol. 25, 2660–2672 (2005).
  Article Google Scholar
• Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005). References 5–9 report for the first time the existence of senescence associated with pre-malignant stages of tumorigenesis both in mouse tumour models and in human neoplastic lesions.
  Article CAS Google Scholar
• Lin, A. W. et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12, 3008–3019 (1998).
  Article CAS Google Scholar
• Zhu, J., Woods, D., McMahon, M. & Bishop, J. M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12, 2997–3007 (1998).
  Article CAS Google Scholar
• Morton, J. P. et al. Mutant but not knockout p53 drives metastatic pancreatic cancer. Proc. Natl Acad. Sci. USA (in the press).
• Tuveson, D. A. et al. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375–387 (2004).
  Article CAS Google Scholar
• Dankort, D. et al. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev. 21, 379–384 (2007).
  Article CAS Google Scholar
• Dhomen, N. et al. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell 15, 294–303 (2009).
  Article CAS Google Scholar
• Sarkisian, C. J. et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biol. 9, 493–505 (2007). This paper elegantly demonstrates that tumour formation by oncogenic HRAS requires high levels of expression of the oncogene, whereas low levels do not lead to tumours. The tumours produced by high HRAS only progress to a pre-malignant stage owing to the engagement of senescence. Genetic ablation of Trp53 or Cdkn2a eliminates senescence and allows progression to full malignancy.
  Article CAS Google Scholar
• Chen, X. et al. Endogenous expression of HrasG12V induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc. Natl Acad. Sci. USA 106, 7979–7984 (2009).
  Article CAS Google Scholar
• Mo, L. et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J. Clin. Invest. 117, 314–325 (2007).
  Article CAS Google Scholar
• Yamakoshi, K. et al. Real-time in vivo imaging of p16Ink4a reveals cross talk with p53. J. Cell Biol. 186, 393–407 (2009).
  Article CAS Google Scholar
• Sun, P. et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 128, 295–308 (2007).
  Article CAS Google Scholar
• Sears, R. C. & Nevins, J. R. Signaling networks that link cell proliferation and cell fate. J. Biol. Chem. 277, 11617–11620 (2002).
  Article CAS Google Scholar
• Majumder, P. K. et al. A prostatic intraepithelial neoplasia-dependent p27Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14, 146–155 (2008).
  Article CAS Google Scholar
• Nardella, C. et al. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev. 22, 2172–2177 (2008).
  Article CAS Google Scholar
• Young, A. P. et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nature Cell Biol. 10, 361–369 (2008).
  Article CAS Google Scholar
• Xu, M. et al. β-catenin expression results in p53-independent DNA damage and oncogene-induced senescence in prelymphomagenic thymocytes in vivo. Mol. Cell. Biol. 28, 1713–1723 (2008).
  Article CAS Google Scholar
• Acosta, J. C. et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 133, 1006–1018 (2008).
  Article CAS Google Scholar
• Courtois-Cox, S. et al. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10, 459–472 (2006).
  Article CAS Google Scholar
• Bartkova, J. et al. _Oncogene_-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633–637 (2006).
  Article CAS Google Scholar
• Fujita, K. et al. p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence. Nature Cell Biol. 11, 1135–1142 (2009).
  Article CAS Google Scholar
• Kuilman, T. et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133, 1019–1031 (2008).
  Article CAS Google Scholar
• Gray-Schopfer, V. C. et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496–505 (2006).
  Article CAS Google Scholar
• Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703–716 (2003).
  Article CAS Google Scholar
• Goel, V. K. et al. Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice. Oncogene 28, 2289–2298 (2009).
  Article CAS Google Scholar
• Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111–120 (2003).
  Article CAS Google Scholar
• Schuhmacher, A. J. et al. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J. Clin. Invest. 118, 2169–2179 (2008).
  CAS PubMed PubMed Central Google Scholar
• Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nature Rev. Cancer 7, 295–308 (2007).
  Article CAS Google Scholar
• Santoriello, C. et al. Expression of H-RASV12 in a zebrafish model of Costello syndrome causes cellular senescence in adult proliferating cells. Dis. Model Mech. 2, 56–67 (2009).
  Article CAS Google Scholar
• Cosme-Blanco, W. et al. Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence. EMBO Rep. 8, 497–503 (2007).
  Article CAS Google Scholar
• Feldser, D. M. & Greider, C. W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 11, 461–469 (2007).
  Article CAS Google Scholar
• Deng, Y., Chan, S. S. & Chang, S. Telomere dysfunction and tumour suppression: the senescence connection. Nature Rev. Cancer 8, 450–458 (2008).
  Article CAS Google Scholar
• Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661–665 (2007). This paper used sophisticated genetically manipulated mice engineered to switch the tumour suppressor p53 off and on. Tumours that developed in the absence of p53 were efficiently controlled and regressed after re-expression of p53 and, for some of the tumour types, the mechanism restraining tumour progression was demonstrated to be cellular senescence.
  Article CAS Google Scholar
• Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007). Following from reference 41, the authors identified cells of the innate immune system as responsible for clearing senescent tumour cells and for the ensuing tumour regression.
  Article CAS Google Scholar
• Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R. & Lane, D. P. Awakening guardian angels: drugging the p53 pathway. Nature Rev. Cancer 9, 862–873 (2009).
  Article CAS Google Scholar
• Efeyan, A. et al. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Cancer Res. 67, 7350–7357 (2007).
  Article CAS Google Scholar
• Kumamoto, K. et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 68, 3193–3203 (2008).
  Article CAS Google Scholar
• Wu, C. H. et al. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc. Natl Acad. Sci. USA 104, 13028–13033 (2007). An elegant demonstration of the concept that elimination of an oncogene necessary for tumour maintenance, in this case MYC, can result in tumour regression associated with senescence.
  Article CAS Google Scholar
• Soucek, L. et al. Modelling Myc inhibition as a cancer therapy. Nature 455, 679–683 (2008).
  Article CAS Google Scholar
• Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335–346 (2002).
  Article CAS Google Scholar
• Roninson, I. B. Tumor cell senescence in cancer treatment. Cancer Res. 63, 2705–2715 (2003).
  CAS PubMed Google Scholar
• Cleator, S., Parton, M. & Dowsett, M. The biology of neoadjuvant chemotherapy for breast cancer. Endocr. Relat Cancer 9, 183–195 (2002).
  Article CAS Google Scholar
• Roberson, R. S., Kussick, S. J., Vallieres, E., Chen, S. Y. & Wu, D. Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 65, 2795–2803 (2005).
  Article CAS Google Scholar
• te Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J. & Joel, S. P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 62, 1876–1883 (2002).
  CAS PubMed Google Scholar
• Coppe, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).
  Article CAS Google Scholar
• Collado, M. & Serrano, M. The power and the promise of oncogene-induced senescence markers. Nature Rev. Cancer 6, 472–476 (2006).
  Article CAS Google Scholar
• Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363–9367 (1995).
  Article CAS Google Scholar
• Kurz, D. J., Decary, S., Hong, Y. & Erusalimsky, J. D. Senescence-associated β-galactosidase reflects an increase in lysosomal mass during replicative ageing of human endothelial cells. J. Cell Sci. 113, 3613–3622 (2000).
  CAS PubMed Google Scholar
• Yang, N. C. & Hu, M. L. The limitations and validities of senescence associated-β-galactosidase activity as an aging marker for human foreskin fibroblast Hs68 cells. Exp. Gerontol. 40, 813–819 (2005).
  Article CAS Google Scholar
• Shamma, A. et al. Rb regulates DNA damage response and cellular senescence through E2F-dependent suppression of N-ras isoprenylation. Cancer Cell 15, 255–269 (2009).
  Article CAS Google Scholar